TITLE:
Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients

CONDITION:
Acromegaly

INTERVENTION:
Pasireotide (SOM230), Octreotide (Sandostatin)

SUMMARY:

      5 month study comparing SOM230 s.c. and Sandostatin s.c. in acromegalic patients.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 80 Years
Criteria:

        Inclusion Criteria:

          -  Patients with active acromegaly due to a pituitary adenoma

          -  Patients who have been previously treated for acromegaly with certain medications may
             be required to be without certain medications prior to entering the study

        Exclusion Criteria:

          -  Patients with compression of the optic chiasm causing any visual field defect

          -  Patients who require a surgical intervention for relief of any sign or symptom
             associated with tumor compression

          -  Patients who have received radiotherapy in the 2 years prior to the start of the
             trial

          -  Patients who have congestive heart failure, unstable angina, cardia arrhythmia, or a
             history of acute myocardial infarction within the three months preceding enrollment

          -  Patients with gallstone disease

          -  Patients with chronic liver disease

          -  Known hypersensitivity to Sandostatin or Sandostatin LAR

          -  Female patients who are pregnant or lactating, or are of childbearing potential and
             not practicing a medically acceptable method of birth control and highly effective
             method for birth control

          -  History of immunocompromise, including a positive HIV test result

          -  Patients who have a history of alcohol or drug abuse in the six-month period prior to
             the enrollment visit

          -  Patients who have participated in any clinical investigation with an investigational
             drug within 4 weeks prior to dosing
      
